Overview
REPL market data
Price History
REPL price chart · 1M
- O
- 15.60
- H
- 15.98
- L
- 15.07
- C
- 15.88
- Vol
- 224,418.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $15.60
- Previous Close
- $15.80
- Day High
- $15.98
- Day Low
- $15.07
- 52 Week High
- $15.98
- 52 Week Low
- $1.50
- 7 Day Return
- +7.30%
- 30 Day Return
- +83.90%
- 90 Day Return
- +239.32%
- 1 Year Return
- +97.02%
- Daily Notional Volume
- $3.6M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.91 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.50 – $15.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 3.80.
Company News
JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21Benzinga · Aug 26, 2026, 1:39 PM
Replimune Group Files Shelf Prospectus For Offering; Size Not DisclosedBenzinga · Aug 14, 2026, 8:55 PM
8-K filing — Replimune Group, Inc. (REPL)SEC EDGAR · Aug 14, 2026, 12:10 PM
Replimune Group Q1 EPS $(0.72) Beats $(0.73) EstimateBenzinga · Aug 14, 2026, 12:06 PM
Replimune Group shares are trading higher. The company anounced the pricing of its $150 million underwritten offering.Benzinga · Aug 10, 2026, 2:57 PM
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per UnitBenzinga · Aug 10, 2026, 12:10 PM
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19Benzinga · Aug 7, 2026, 1:48 PM
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer TreatmentBenzinga · Aug 7, 2026, 11:49 AM
Replimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous MelanomaBenzinga · Aug 6, 2026, 8:03 PM
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the FirmGlobenewswire Inc · Aug 5, 2026, 10:02 PM